ArticleMolecular diversity2026
Structural insights into TLR4 activation by SARS-CoV-2 spike protein: implications for inflammatory response modulation.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mast cells release DNA Extracellular Traps (DETs) in response to SARS-CoV-2 and its spike protein.Cell communication and signaling : CCS · 2026Article
- Mesenchymal Stromal Cells Respond to SARS-CoV-2 Peptides and Exhibit Altered T-Cell Regulatory Capacity.Cells · 2026Article
- Cardiac Tissue Damage in a Female Animal Post-COVID Model: Relevance of Chemokine-Mediated Inflammation.Viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toll-like receptor 4 (TLR4) in complex with myeloid differentiation factor 2 (MD2) plays a central role in innate immune sensing and inflammatory responses during viral infections. Emerging evidence suggests that viral glycoproteins, including the SARS-CoV-2 spike (S) protein, can aberrantly activate TLR4, contributing to cytokine storms; however, the molecular basis remains unclear. In this study, we investigated the recognition of the SARS-CoV-2 spike protein, in both its monomeric and trimeric forms, by the TLR4/MD2 receptor complex using a comprehensive in silico framework. Protein-protein docking, extended molecular dynamics simulations (500 ns), interaction profiling, principal component analysis, free energy landscape mapping, and binding-affinity calculations were employed. The S1 subunit, particularly the receptor-binding domain (RBD) and N-terminal domain (NTD), emerged as the principal interface for TLR4 and MD2-a novel finding. The spike monomer exhibited stronger and more stable interactions than the trimer, supported by a greater number of hydrogen bonds and salt bridges, lower binding energies, and distinct PCA/energy landscape features. Two N-linked glycosylation sites in the monomer were positioned proximal to the MD2 binding pocket, compared to one in the trimer, suggesting a possible role in modulating receptor activation. Several hotspot residues were also identified as potential therapeutic targets. Collectively, these findings support a model in which the SARS-CoV-2 spike protein engages TLR4/MD2 through domain-specific interactions that may modulate innate immune signalling.
Indexed as
Identifiers
40946135What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.